GlassScriptPhysician profile
Mohan K Krishnamachary
NPI 1588625099
$14,962.40
in general payments reported to CMS, 2019-2025
44 companies · $7,959 in 2025
The $7,959 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.33 · 2020: $225 · 2021: $198 · 2022: $318 · 2023: $3,550 · 2024: $2,670 · 2025: $7,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,850 · Food and Beverage: $4,810 · Education: $401 · Travel and Lodging: $87.32 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,850.00 |
| Food and Beverage | $4,810.40 |
| Education | $401.03 |
| Travel and Lodging | $87.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,832.85 | 2022-2025 | |
| Janssen Biotech, INC. | $3,847.15 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $1,610.23 | 2022-2024 | Alunbrig, Ninlaro, Iclusig |
| Seagen INC. | $674.48 | 2021-2025 | Tukysa, Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $511.17 | 2020-2025 | Lynparza, Calquence, Enhertu |
| Astellas Pharma US INC | $358.24 | 2020-2025 | Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $332.42 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Scientific Affairs, LLC | $297.14 | 2023-2024 | Darzalex, Carvykti, Tecvayli |
| Abbvie INC. | $283.57 | 2023-2025 | |
| Daiichi Sankyo INC. | $266.11 | 2022-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $194.07 | 2022-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $183.56 | 2019-2025 | Tecentriq, Rozlytrek, Alecensa |
| Incyte Corporation | $158.30 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $141.03 | 2022-2024 | |
| Puma Biotechnology, INC. | $133.71 | 2023 | Nerlynx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $124.88 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $92.67 | 2020-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $89.09 | 2023-2024 | Opdivo |
| Gilead Sciences, INC. | $85.56 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $64.22 | 2022-2024 | Shingrix, Ojjaara |
| Coherus Oncology, INC. | $55.25 | 2023-2024 | |
| Amgen INC. | $53.93 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Beigene USA, INC. | $53.86 | 2022-2024 | Brukinsa, Tevimbra |
| Mirati Therapeutics, INC. | $53.77 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $43.10 | 2023-2025 | Orserdu |
| Celgene Corporation | $42.06 | 2023-2025 | Reblozyl |
| Array Biopharma INC | $34.80 | 2025 | Braftovi, Tukysa, Mektovi |
| Deciphera Pharmaceuticals INC. | $33.88 | 2023-2024 | Qinlock |
| Jazz Pharmaceuticals INC. | $31.45 | 2023 | |
| Karyopharm Therapeutics INC. | $22.79 | 2023 | Xpovio |
| Intuitive Surgical, INC. | $22.00 | 2022 | |
| Boston Scientific Corporation | $21.86 | 2023 | |
| Eisai INC. | $21.50 | 2022 | |
| Dendreon Pharmaceuticals LLC | $21.24 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $19.99 | 2024 | Cosela |
| Beone Medicines USA, INC. | $19.25 | 2025 | Brukinsa |
| Lilly USA, LLC | $18.40 | 2023 | Verzenio, Jaypirca |
| Genzyme Corporation | $17.52 | 2025 | |
| Geron Corporation | $16.73 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $16.43 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $16.13 | 2022 | |
| Kite Pharma, INC. | $15.61 | 2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $15.31 | 2023 | Ultomiris |
| Myriad Genetic Laboratories, INC. | $15.09 | 2024 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Krishnamachary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.